Generation Bio chief scientific officer Matthew Stanton to leave role

Generation Bio (GBIO) announced it is leveraging its validated T cell-directed lipid nanoparticle to develop siRNA therapeutics to silence disease-driving targets in T cells. siRNA delivered with ctLNP aims to modulate T cell function without impacting the function of the broader immune system. ctLNP-siRNA could reach targets that change how auto-reactive T cells activate, differentiate, migrate, and damage tissues. Generation Bio will provide further details about its lead ctLNP-siRNA programs in upcoming quarters and expects to submit its first IND in the second half of 2026. The company is reorganizing to support the clinical development of T cell-directed medicines. In addition, the company is announcing changes to its executive leadership team. Phillip Samayoa, chief strategy officer, will succeed Matthew Stanton as chief scientific officer. Stanton will remain with the company through mid-2025 and transition to its scientific advisory board thereafter. Kevin Conway, the company’s head of finance, has been elected chief financial officer to succeed Matthew Norkunas. Generation Bio also expects to appoint a chief medical officer in 2025.